Michail Shipitsin

• Exploring the evolving role of biomarkers in DDR therapy, from predictive tools to dynamic response monitors

• Evaluate the challenges of biomarker complexity, standardization, and clinical implementation

• Sharing cross-sector insights on integrating biomarkers into trial design, dosing strategies, and regulatory pathways